<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=875423625897521&amp;ev=PageView&amp;noscript=1">
Customer Login


Hear more from our team:

Prescription Drug Coverage for Persons with CKD - 2018

By Susan Eymann, MS09 Mar 2020

(Gleaned from the 2018 USRDS Annual Data Report: Volume 1, Chapter 8: www.usrds.org)

Pharmaceutical therapy serves as a critical part of CKD treatment in order to control and reduce complications and delay the progression of the disease. Therefore, a new chapter kidney care news-3about prescription drug coverage to persons with chronic kidney disease (CKD) was added to the USRDS 2018 Annual Data Report (ADR), particularly in light of the continuing prescription opioid epidemic.


  • Approximately 73.7% of chronic kidney disease (CKD) patients enrolled in Medicare Part D in 2016, which was slightly higher than general Medicare enrollment at 69.5%.
  • As compared to White beneficiaries (29.3%), much higher proportions of Asian (73.8%) and African American (62.8%) CKD Part D beneficiaries qualified for the Low-Income Subsidy LIS).
  • Among patients with stand-alone Part D Medicare plans, per person per year (PPPY) insurance spending on prescriptions was 1.6 times higher for Medicare patients with CKD ($4,941) than for general beneficiaries ($3,027) in 2016.
  • Total spending for Part D-covered medications in 2016 was more than twice as high for patients with the LIS than for those without, regardless of the presence of CKD. Patient out-of-pocket costs for LIS patients represented only a 1.2% to 1.3% share of these total expenditures, as compared to 25.3% to 27.0% in each of the non-LIS populations.
  • Prescriptions for lipid-lowering agents, antibacterials, renin-angiotensin-aldosterone system inhibitors, and β-adrenergic blocking agents (beta blockers) were each filled by more than 50% of Medicare CKD patients during 2016 CKD patients with Medicare Advantage and managed care coverage showed similar patterns of use for these drug classes.
  • By drug class, the highest medication expenditures for patients with CKD were for antidiabetic agents, followed by antineoplastic agents, antivirals and lipid-lowering agents.
  • In the United States, the overall proportion of CKD patients using prescription non-steroidal anti-inflammatory agents (NSAIDs) was 16.4% and opioids were 43.8%.
    New call-to-action